| |
| |
|
| Insider
Information: |
Baker Brothers Life Sciences Lp |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
15 |
|
| Direct
Shares |
28,278,373 |
|
|
Indirect Shares
|
99,473,529 |
|
|
| Direct
Value |
$950,720,528 |
|
|
|
Indirect Value
|
$2,918,249,471 |
|
|
| Total
Shares |
127,751,902 |
|
|
| Total
Value |
$3,868,969,999 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
1
|
|
Stock
price went up :
|
10
|
0
|
| Stock
price went down : |
3
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
3.3
|
-1.0
|
| Percentage
Gain/Loss : |
 11.9%
|
 -16.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Synageva BioPharma Corp |
GEVA |
Director |
2012-07-13 |
5,077,676 |
|
0 |
Premium* |
|
|
XOMA Corporation |
XOMA |
Director |
2012-07-19 |
13,606,093 |
|
0 |
Premium* |
|
|
Genomic Health Inc |
GHDX |
Director |
2012-07-26 |
9,086,690 |
|
0 |
Premium* |
|
|
Acadia Pharmaceuticals Inc |
ACAD |
Director, 10% Owner |
2023-06-01 |
205,752 |
2023-06-01 |
39,330,977 |
Premium* |
|
|
Seagen Inc |
SGEN |
Former 10% Owner, Dire... |
2023-12-14 |
0 |
2023-12-14 |
0 |
Premium* |
|
|
Incyte Corp |
INCY |
Director, 10% Owner |
2017-09-08 |
119,681 |
2017-09-08 |
822,826 |
Premium* |
|
|
Aceragen, Inc |
ACGN |
Director |
|
0 |
2014-03-10 |
1,613,076 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2017-06-15 |
131,963 |
2017-06-15 |
1,074,556 |
Premium* |
|
|
Beigene Ltd |
BGNE |
Director, 10% Owner |
2023-11-14 |
20,838 |
2023-11-14 |
9,878,124 |
Premium* |
|
|
Talis Biomedical Corp |
TLIS |
Director, 10% Owner |
2021-11-18 |
0 |
2021-11-18 |
7,625,425 |
Premium* |
|
|
Tscan Therapeutics, Inc. |
TCRX |
Director, 10% Owner |
2022-05-10 |
0 |
2022-05-11 |
2,528,583 |
Premium* |
|
|
DBV Technologies SA |
DBVT |
Director, 10% Owner |
2022-06-13 |
0 |
2022-06-13 |
29,190,248 |
Premium* |
|
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
Director |
2023-06-06 |
29,680 |
2023-06-06 |
2,719,343 |
Premium* |
|
|
Igm Biosciences, Inc. |
IGMS |
Director |
2023-06-30 |
0 |
2023-09-29 |
2,896,968 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
Director |
2023-11-14 |
0 |
2023-12-14 |
1,793,403 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
114 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • – |
2013-01-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,229,612 |
|
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2013-05-15 |
4 |
B |
$12.50 |
$24,912,500 |
I/I |
1,993,000 |
389,909 |
2.25 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2013-06-03 |
4 |
B |
$14.00 |
$10,794,615 |
I/I |
767,953 |
406,609 |
2.25 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2013-06-04 |
4 |
B |
$14.42 |
$10,110,693 |
I/I |
699,776 |
421,826 |
2.25 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2013-06-05 |
4 |
B |
$14.46 |
$12,657,999 |
I/I |
872,585 |
440,802 |
2.25 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2023-01-12 |
4 |
OE |
$5.22 |
$156,600 |
I/I |
30,000 |
38,484,981 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2023-05-22 |
4 |
B |
$24.46 |
$3,297,815 |
I/I |
134,206 |
38,607,761 |
2.25 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2023-05-23 |
4 |
B |
$25.33 |
$5,312,458 |
I/I |
209,053 |
38,811,515 |
2.25 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2023-05-23 |
4 |
OE |
$17.01 |
$425,250 |
I/I |
25,000 |
38,620,261 |
0 |
- |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2023-05-24 |
4 |
B |
$25.27 |
$14,096,825 |
I/I |
553,263 |
39,317,673 |
2.25 |
% |
|
| ACAD |
Acadia Pharmaceuticals In... |
Director |
– • • |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
26,608 |
39,330,977 |
0 |
- |
|
| ACGN |
Aceragen, Inc |
Director |
– • – |
2014-03-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,613,076 |
|
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2017-05-10 |
4 |
A |
$0.00 |
$0 |
I/I |
4,060 |
6,106,592 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2017-06-14 |
4 |
B |
$118.00 |
$518,256 |
I/I |
4,392 |
7,321,850 |
2.1 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2017-06-14 |
4 |
B |
$114.33 |
$156,915,444 |
I/I |
1,348,955 |
7,317,906 |
2.1 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2017-06-15 |
4 |
B |
$116.54 |
$77,012,491 |
I/I |
656,387 |
980,146 |
2.1 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • • |
2017-08-11 |
4 |
B |
$71.00 |
$12,499,976 |
I/I |
176,056 |
3,476,256 |
2.25 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • • |
2017-10-13 |
4 |
A |
$0.00 |
$0 |
D/D |
14,204 |
7,102 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • • |
2017-10-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(49,200) |
0 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • • |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
I/I |
66,768 |
67,573 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • • |
2023-11-14 |
4 |
S |
$180.50 |
$198,550,000 |
I/I |
(1,100,000) |
9,691,294 |
0 |
% |
|
| DBVT |
DBV Technologies SA |
Director |
– • • |
2022-06-13 |
4 |
A |
$0.00 |
$0 |
I/I |
11,875,000 |
14,575,984 |
0 |
- |
|
| GHDX |
Genomic Health Inc |
Director |
– • – |
2012-07-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,086,690 |
|
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,108 |
2,896,414 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,108 |
2,896,968 |
0 |
- |
|
114 Records found
|
|
Page 1 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
